Repaglinide-Cyclodextrin complexes: Preparation, Characterization and in vivo evaluation of antihyperglycemic activity

被引:8
作者
Desai, Neha S. [1 ]
Bramhane, Dinesh M. [1 ]
Nagarsenker, Mangal S. [1 ]
机构
[1] Bombay Coll Pharm, Dept Pharmaceut, Bombay 400098, Maharashtra, India
关键词
Repaglinide; beta-Cyclodextrin; Hydroxypropyl-beta-cyclodextrin; In vitro dissolution; In vivo study; BETA-CYCLODEXTRIN; PHARMACEUTICAL APPLICATIONS; INCLUSION COMPLEXES;
D O I
10.1007/s10847-010-9895-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The influence of beta-cyclodextrin (beta CD) and its hydrophilic derivative hydroxypropyl-beta-cyclodextrin (HP beta CD) on the in vitro dissolution rate and in vivo antihyperglycemic activity of a poorly water soluble drug, repaglinide (RPG) was studied. Solid dispersions of RPG were prepared by various methods such as physical mixing, cogrinding, kneading, and coevaporation. The dispersions were characterized by differential scanning calorimetry (DSC), X-ray diffraction patterns, infrared spectroscopy, nuclear magnetic resonance studies and optical microscopy. The DSC thermogram of HP beta CD dispersion indicated complete disappearance of melting endotherm of RPG indicating complete amorphization. The dispersions exhibited faster rates of dissolution compared to that of physical mixtures. The kneaded dispersion with HP beta CD exhibited the fastest in vitro dissolution rate when compared to other dispersions. In vivo studies revealed that the kneaded dispersions with beta CD and HP beta CD showed significant improvement in antihyperglycemic activity as compared to RPG alone, thus confirming the advantage of improved pharmacological activity of RPG when administered as a solid dispersion with cyclodextrin.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 20 条
[1]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[2]   Meglitinide analogues:: a review of clinical data focused on recent trials [J].
Blicklé, JF .
DIABETES & METABOLISM, 2006, 32 (02) :113-120
[3]   Repaglinide - A review of its therapeutic use in type 2 diabetes mellitus [J].
Culy, CR ;
Jarvis, B .
DRUGS, 2001, 61 (11) :1625-1660
[4]   Cyclodextrins and their uses: a review [J].
Del Valle, EMM .
PROCESS BIOCHEMISTRY, 2004, 39 (09) :1033-1046
[5]   HIGH-FIELD NUCLEAR-MAGNETIC-RESONANCE TECHNIQUES FOR THE INVESTIGATION OF A BETA-CYCLODEXTRIN-INDOMETHACIN INCLUSION COMPLEX [J].
DJEDAINI, F ;
LIN, SZ ;
PERLY, B ;
WOUESSIDJEWE, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (07) :643-646
[6]  
Gordon B., 1999, INT J PHARMACEUT, V179, P65
[7]  
Higuchi T., 1965, Adv. Anal. Chem. Instrum., V4, P117, DOI DOI 10.1016/S0076-6879(82)87029-8
[8]   Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta-cyclodextrin [J].
Jordheim, Lars Petter ;
Degobert, Ghania ;
Diab, Roudayna ;
Peyrottes, Suzanne ;
Perigaud, Christian ;
Dumontet, Charles ;
Fessi, Hatem .
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2009, 63 (1-2) :11-16
[9]   CONCEPT OF DISSOLUTION EFFICIENCY [J].
KHAN, KA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1975, 27 (01) :48-49
[10]   Pharmaceutical applications of cyclodextrins .1. Drug solubilization and stabilization [J].
Loftsson, T ;
Brewster, ME .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (10) :1017-1025